Recombinant CD19 (Inebilizumab Biosimilar) antibody
Research Grade
Reactivity: Human
ELISA
Host: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Target See all CD19 (Inebilizumab Biosimilar) products
- CD19 (Inebilizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
-
Mammalian Cells
- Expression System
- Mammalian cells
-
Clonality
- Monoclonal
-
Conjugate
- This CD19 (Inebilizumab Biosimilar) antibody is un-conjugated
-
Application
- ELISA
- Purpose
- Inebilizumab Biosimilar - Anti-CD19 mAb
- Characteristics
- Antibody Type: IgG1-kappa
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Grade
- Research Grade
- Isotype
- IgG1 kappa
-
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS pH 7.5
- Storage
- -80 °C
- Storage Comment
- store at -80°C
-
- Target
- CD19 (Inebilizumab Biosimilar)
- Abstract
- CD19 (Inebilizumab Biosimilar) Products
- Target Type
- Biosimilar
- Background
-
MEDI-551
Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody that targets the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, which may be usefull to treat neuromyelitis optica spectrum disorder (NMOSD)through B-cell depletion. - CAS-No
- 1299440-37-1
-
You are here:
